[For a reform of the legislation applied to plasma derivatives].
The French system of law concerning marketing authorisations for blood-derived medicines is currently being contested by foreign laboratories claiming that our legislation limits the importation of medicines developed from remunerated blood and plasma donation. This criticism is not entirely founded; nonetheless, it would be judicious to bring about at least three reforms of the system of production and sales of blood-derived medicines in order to improve its safety and effectiveness while at the same time creating conditions necessary for ethical competition between different laboratories.